AVEO Pharmaceuticals Executives
AVEO Pharmaceuticals employs about 114 people. The company is managed by 24 executives with a total tenure of roughly 140 years, averaging almost 5.0 years of service per executive, having 4.75 employees per reported executive. Analysis of AVEO Pharmaceuticals' management performance can provide insight into the firm performance.
Michael Bailey CEO CEO and President Secretary and Director |
Henri Termeer Chairman Independent Chairman of the Board |
AVEO |
AVEO Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.1456) % which means that it has lost $0.1456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7253) %, meaning that it created substantial loss on money invested by shareholders. AVEO Pharmaceuticals' management efficiency ratios could be used to measure how well AVEO Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.AVEO Pharmaceuticals Workforce Comparison
AVEO Pharmaceuticals is rated third in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 78,109. AVEO Pharmaceuticals adds roughly 114 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (0.31) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.26) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.26. AVEO Pharmaceuticals Notable Stakeholders
An AVEO Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AVEO Pharmaceuticals often face trade-offs trying to please all of them. AVEO Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AVEO Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Bailey | CEO and President Secretary and Director | Profile | |
Henri Termeer | Independent Chairman of the Board | Profile | |
Mike Ferraresso | Vice President - Business Analytics and Commercial Operations | Profile | |
Nikhil Mehta | Senior Vice President - Regulatory and Quality Assurance | Profile | |
Karuna Rubin | Senior Vice President General Counsel | Profile | |
Keith Ehrlich | CFO | Profile | |
Matthew Dallas | CFO | Profile | |
Robert Young | Independent Director | Profile | |
Raju Kucherlapati | Independent Director | Profile | |
Kenneth Bate | Independent Director | Profile | |
Anthony Evnin | Independent Director | Profile | |
John Johnson | Independent Director | Profile | |
Gregory Mayes | Independent Director | Profile | |
Kevin Peacock | VP Marketing | Profile | |
Danielle Holland | VP Sec | Profile | |
David Crist | VP Sales | Profile | |
Michael Needle | Chief Medical Officer | Profile | |
Michael Ferraresso | Chief Officer | Profile | |
Jeb Ledell | Chief Officer | Profile | |
Catherine DeRose | VP HR | Profile | |
Lisa Bruneau | VP Treasurer | Profile | |
Emile Farhan | VP Operations | Profile | |
CPA CFA | Chief Officer | Profile | |
Monique Allaire | IR Contact Officer | Profile |
About AVEO Pharmaceuticals Management Performance
The success or failure of an entity such as AVEO Pharmaceuticals often depends on how effective the management is. AVEO Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AVEO management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AVEO management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts. Aveo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 114 people.
The data published in AVEO Pharmaceuticals' official financial statements usually reflect AVEO Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AVEO Pharmaceuticals. For example, before you start analyzing numbers published by AVEO accountants, it's critical to develop an understanding of what AVEO Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of AVEO Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AVEO Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AVEO Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AVEO Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of AVEO Pharmaceuticals' management manipulating its earnings.
AVEO Pharmaceuticals Workforce Analysis
Traditionally, organizations such as AVEO Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AVEO Pharmaceuticals within its industry.AVEO Pharmaceuticals Manpower Efficiency
Return on AVEO Pharmaceuticals Manpower
Revenue Per Employee | 341K | |
Revenue Per Executive | 1.6M | |
Net Loss Per Employee | 467.9K | |
Net Loss Per Executive | 2.2M | |
Working Capital Per Employee | 245.4K | |
Working Capital Per Executive | 1.2M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the AVEO Pharmaceuticals information on this page should be used as a complementary analysis to other AVEO Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in AVEO Stock
If you are still planning to invest in AVEO Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AVEO Pharmaceuticals' history and understand the potential risks before investing.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |